# Melanotan I Peptide

> Melanotan I is afamelanotide, an alpha-MSH analog that activates melanocortin signaling, increases eumelanin, and supports photoprotection.

Canonical: https://pepflow.app/peptides/melanotan-i/

The Photoprotection Analog

Melanotan I is afamelanotide, a synthetic alpha-MSH analog and melanocortin agonist. Scenesse is a prescription subcutaneous implant for erythropoietic protoporphyria.

Skin appearance

Tier B

Evidence Strong

Safety Well-Studied

FDA status Approved

Last reviewed October 25, 2026 37 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Melanotan I?

Melanotan I is afamelanotide, a synthetic alpha-MSH analog and melanocortin agonist. Scenesse is a prescription subcutaneous implant for erythropoietic protoporphyria.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

Its high-confidence use is photoprotection in EPP, where increased eumelanin helps patients tolerate light exposure better.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

Melanotan I is distinct from Melanotan II. Afamelanotide has a regulated implant product and disease indication; Melanotan II is an unapproved tanning peptide with broader receptor activity.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

## What Melanotan I is investigated for

Melanotan I evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### EPP photoprotection Injectable 82% Strong

EPP photoprotection is the high-confidence Melanotan I/afamelanotide indication.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>)

#### Human evidence

FDA labeling and pivotal human trials support afamelanotide implant use for EPP photoprotection.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>)

#### Animal / mechanistic evidence

The photoprotective rationale follows alpha-MSH melanocortin activity and eumelanin induction.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>)

### ### Vitiligo repigmentation with phototherapy Injectable 58% Emerging

Vitiligo repigmentation is human-studied but separate from approved EPP photoprotection.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/25230094/>)

#### Human evidence

A randomized multicenter trial evaluated afamelanotide with narrowband UV-B phototherapy for nonsegmental vitiligo.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/25230094/>)

#### Animal / mechanistic evidence

The rationale is melanocortin-driven pigmentation combined with phototherapy-induced repigmentation.[\[34\]](<https://pubmed.ncbi.nlm.nih.gov/25230094/>)

### ### UV-free tanning and photoprotection Injectable 56% Emerging

Pigmentation and tanning should be lower confidence than EPP and must not imply cosmetic approval.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/25470471/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/21073357/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

#### Human evidence

Human afamelanotide phototoxicity and photoprotection studies support pigmentation discussion, but cosmetic tanning is not the same as EPP treatment.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/25470471/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/21073357/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

#### Animal / mechanistic evidence

Melanocortin receptor activation supports eumelanin and photoprotection mechanisms.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/25470471/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/21073357/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

### ### Acute stroke neuroprotection Injectable 35% Preliminary

Acute stroke neuroprotection is human-studied at feasibility level, not an established stroke treatment.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/37496004/>)

#### Human evidence

A small open-label feasibility and safety study evaluated afamelanotide in acute stroke patients; it was not definitive efficacy evidence.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/37496004/>)

#### Animal / mechanistic evidence

The stroke rationale is melanocortin-related neuroprotection and vascular biology, separate from EPP photoprotection.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/37496004/>)

### ### Skin DNA-repair biology Injectable 30% Limited

DNA-repair biology helps explain photoprotection interest, but it should not be written as proven skin-cancer prevention or cosmetic sunscreen replacement.[\[19\]](<https://pubmed.ncbi.nlm.nih.gov/24730569/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>)

#### Human evidence

Clinical photoprotection evidence exists for EPP, but DNA-repair enhancement itself is not established as a separate human clinical endpoint.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>)

#### Animal / mechanistic evidence

MC1R and alpha-MSH literature supports reduced UV-induced DNA damage and repair-pathway activation in skin models.[\[19\]](<https://pubmed.ncbi.nlm.nih.gov/24730569/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/15569680/>)

## Evidence snapshot

### Overall confidence

Strong

82%

Afamelanotide has strong support for EPP photoprotection via an approved implant. Cosmetic tanning or Melanotan II-style use does not follow from that indication.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

82%

### Human evidence

Strong

FDA labeling and clinical trials support afamelanotide implant use for EPP photoprotection.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

34%

### Animal / preclinical

Limited

MC1R-driven eumelanin production directly supports the photoprotection mechanism.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

82%

### Mechanism support

Strong

Afamelanotide activates melanocortin-1 receptors on melanocytes, increasing eumelanin production. In EPP, that pigment response can improve photoprotection.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

## Forms & administration

Afamelanotide is supplied as the approved Scenesse implant for erythropoietic protoporphyria, placed by a trained healthcare professional every two calendar months. Its product and schedule differ from unapproved Melanotan I tanning vials and self-injection protocols.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Approved afamelanotide treatment uses a 16 mg implant. Unapproved vial protocols commonly start at 250 mcg.[\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9113347/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

### Frequency

The implant is given every 2 months. Vial protocols use 1 dose daily.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9113347/>)

### Timing Considerations

Implant timing follows the specialist treatment plan.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9113347/>)

### Cycle Length

Implant treatment is ongoing. Vial protocols commonly run 4 weeks.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9113347/>)

[Full Melanotan I dosage guide](<https://pepflow.app/peptides/melanotan-i/dosage/>)

## What to expect

### First 2 months

Subcutaneous afamelanotide implant treatment gradually increases pigmentation and light tolerance in the EPP treatment context.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>)

### Months 3-6

Subcutaneous implant outcomes center on phototoxic symptoms, pain-free light exposure, outdoor activity, and dermatology skin checks.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>)

### After stopping

Pigmentation and photoprotection gradually fade after subcutaneous afamelanotide implants stop as exposure and skin turnover change.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>)

## Safety profile

Melanotan I safety should separate SCENESSE implant labeling for EPP from non-label tanning use. Skin monitoring, implant-site reactions, nausea, fatigue, and pigmentation matter.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

### Common side effects

- Implant-site reactions [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- Nausea [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- Fatigue [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- Dizziness [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

### Cautions

- Skin monitoring[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- Specialist implant use[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- Non-label tanning[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

### What we don't know

Cosmetic tanning protocols and self-injected products are separate from the SCENESSE EPP label and have different safety uncertainty.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

## Who Melanotan I is not for

Route-specific avoid and medical-review notes:

- **Use outside label without clinician oversight**

  Use outside label without clinician oversight warrants medical review or avoidance for Melanotan I.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)
- **Concerning moles without dermatology review**

  Concerning moles without dermatology review warrants medical review or avoidance for Melanotan I.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)
- **Pregnancy or breastfeeding unless specifically supervised**

  Pregnancy or breastfeeding unless specifically supervised warrants medical review or avoidance for Melanotan I.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Photosensitizers / UV exposure**

  Photosensitizing drugs and intentional UV tanning can change burn, pigmentation, and skin-monitoring decisions; this is a route-specific caution.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- **Melanocortin tanning products**

  Melanotan II, bremelanotide, or other melanocortin products can stack pigmentation, nausea, and vascular effects; this is a theoretical pathway caution.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- **Immunosuppressants / skin risk**

  Immunosuppressants or therapies that raise skin-cancer risk can change dermatology monitoring decisions; this is a route-specific caution.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

## Pairing notes

### Not recommended with

**Melanotan II: overlapping pigmentation effects** Injectable

Melanotan I and Melanotan II both activate melanocortin pathways that increase pigmentation. Using both duplicates melanocortin exposure, while Melanotan II also adds nausea, sexual-response, and poorly characterized systemic effects.[\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9113347/>) [\[35\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[36\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

**PT-141: overlapping melanocortin signaling** Injectable

Melanotan I and PT-141 both activate melanocortin receptors, although they are used for different effects. Combined exposure has no validated benefit and can make pigmentation, nausea, and systemic effects harder to attribute.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[37\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, SCENESSE afamelanotide is FDA-approved for erythropoietic protoporphyria photoprotection. Cosmetic tanning, self-injected Melanotan I, and compounded products are outside that approved implant program.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[22\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Approved · SCENESSE afamelanotide implant is FDA-approved for erythropoietic protoporphyria photoprotection; cosmetic tanning products or self-injected Melanotan I are separate.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) | Not Listed · 503A compounding for Melanotan I is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[22\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Approved

SCENESSE afamelanotide implant is FDA-approved for erythropoietic protoporphyria photoprotection; cosmetic tanning products or self-injected Melanotan I are separate.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>)

503A compounding

Not Listed

503A compounding for Melanotan I is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved.[\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[22\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets.[\[25\]](<https://www.ema.europa.eu/en/medicines>) [\[26\]](<https://products.mhra.gov.uk/>) [\[27\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[28\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA does not list Melanotan I here as S2 in the same way as GH or gonadotropins, but non-approved systemic, wellness, or compounded use can still require S0-style anti-doping review.[\[17\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[22\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[23\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Melanotan I, clinically developed as afamelanotide, activates melanocortin-1 receptors on melanocytes and increases eumelanin production. In plain terms, it darkens pigment in a way that can improve photoprotection for erythropoietic protoporphyria patients.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

Delivery and indication define the mechanism. The approved afamelanotide context uses an implant under medical supervision with phototoxic disease monitoring; that is not equivalent to casual tanning injections, research-market vials, or unsupervised pigment manipulation. The route, implant format, and disease context are what make the pharmacology clinically interpretable.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

## Research gaps & open questions

What the current literature has not yet settled about Melanotan I:

01

Trials need to show whether afamelanotide or Melanotan I is useful for tanning, skin disease, or other uses outside erythropoietic protoporphyria (EPP).[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

02

Long-term studies outside approved EPP care should track persistent pigmentation, changes in moles, and other skin outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

03

Research and product labeling need to clearly distinguish approved afamelanotide implants from unapproved Melanotan I and Melanotan II products, which are not interchangeable.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

## Common questions

### Is Melanotan I FDA-approved?

Yes. Afamelanotide is FDA-approved as SCENESSE for EPP photoprotection; that is not approval for cosmetic tanning.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

### Is Melanotan I the same as Melanotan II?

No. Afamelanotide has a disease-specific approved implant product; Melanotan II is an unapproved systemic tanning peptide.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

### Is it approved for cosmetic tanning?

No. Melanotan I is not FDA-approved for cosmetic tanning; SCENESSE is approved for EPP photoprotection.[\[15\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)

## Myths & misconceptions

### Myth

Scenesse approval means melanotan is approved for tanning.

### Reality

Approval is for EPP photoprotection, not cosmetic tanning.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

### Myth

All melanotan peptides are interchangeable.

### Reality

Receptor selectivity, route, evidence, and regulatory status differ.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)

## History & discovery

Melanotan I developed into afamelanotide, an alpha-MSH analog aimed at increasing eumelanin and photoprotection. Its history is disease-specific rather than a general tanning-product story. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>)

Clinical studies in erythropoietic protoporphyria tested whether afamelanotide could increase pain-free light exposure. That established photoprotection as the main outcome, not cosmetic tanning.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>)

FDA approval of SCENESSE created a supervised implant precedent for adult EPP patients. The milestone narrowed the route and indication, separating afamelanotide from unapproved tanning injections.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/26132941/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/26979527/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/33507118/>) [\[14\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>)

## Published research 37 citations

- [\[1\] **Afamelanotide for Erythropoietic Protoporphyria.** N Engl J Med, 2015 Jul 2. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26132941/>)
- [\[2\] **Afamelanotide: A Review in Erythropoietic Protoporphyria.** Am J Clin Dermatol, 2016 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/26979527/>)
- [\[3\] **Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.** Expert Rev Clin Pharmacol, 2021 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/33507118/>)
- [\[4\] **Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.** Expert Rev Clin Pharmacol, 2015 Jan. review.](<https://pubmed.ncbi.nlm.nih.gov/25470471/>)
- [\[5\] **Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.** Br J Dermatol, 2024 Aug 14. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/38736212/>)
- [\[6\] **Advances in the management of erythropoietic protoporphyria - role of afamelanotide.** Appl Clin Genet, 2016. review.](<https://pubmed.ncbi.nlm.nih.gov/28003770/>)
- [\[7\] **Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.** Expert Opin Investig Drugs, 2010 Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/21073357/>)
- [\[8\] **The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study.** Br J Dermatol, 2024 Aug 14. review.](<https://pubmed.ncbi.nlm.nih.gov/38634774/>)
- [\[9\] **German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).** Photodermatol Photoimmunol Photomed, 2025 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40082741/>)
- [\[10\] **\[Porphyrias-what is verified?\].** Internist (Berl), 2018 Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/30328490/>)
- [\[11\] **A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.** J Pharm Biomed Anal, 2013 Mar 5. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/23277150/>)
- [\[12\] **Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.** Orphanet J Rare Dis, 2020 Aug 18. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/32811524/>)
- [\[13\] **Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide (\[Nle4-D-Phe7\]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.** Skin Pharmacol Physiol, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25402764/>)
- [\[14\] **SCENESSE afamelanotide implant prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf>)
- [\[15\] **Drugs@FDA/openFDA query for Melanotan I** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20I%22&limit=1>)
- [\[16\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[17\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[18\] **A feasibility and safety study of afamelanotide in acute stroke patients.** PubMed, 2023. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37496004/>)
- [\[19\] **Significance of the melanocortin 1 receptor in the DNA damage response to ultraviolet radiation.** PubMed, 2014. review.](<https://pubmed.ncbi.nlm.nih.gov/24730569/>)
- [\[20\] **Alpha-melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage.** PubMed, 2005. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/15569680/>)
- [\[21\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[22\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[23\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[24\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[25\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[26\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[27\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[28\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[29\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[30\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[31\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[32\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)
- [\[33\] **Skin pigmentation and pharmacokinetics of melanotan-I in humans.** Biopharm Drug Dispos, 1997 Apr. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/9113347/>)
- [\[34\] **Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.** JAMA Dermatol, 2015 Jan. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/25230094/>)
- [\[35\] **Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.** Life Sci, 1996. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)
- [\[36\] **Melanotan and other injectable tanning products** Therapeutic Goods Administration. regulatory.](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)
- [\[37\] **Vyleesi bremelanotide prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Melanocortin pathway peptide

**Tier**

B

**Evidence**

82% Strong

**Safety**

Well-Studied

**FDA status**

Approved

**Injectable 503A**

Not Listed

**Citations**

[37 citations](<https://pepflow.app/peptides/melanotan-i/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- EPP photoprotection
- Vitiligo repigmentation with phototherapy
- UV-free tanning and photoprotection
- Acute stroke neuroprotection
- Skin DNA-repair biology

### Common side effects

- Implant-site reactions
- Nausea
- Fatigue

### Also known as

- Afamelanotide
- Scenesse
- NDP-alpha-MSH
- MT-I

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Melanotan I dosage guide](<https://pepflow.app/peptides/melanotan-i/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
